These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 30918134)

  • 1. Circulating zinc-α2-glycoprotein is reduced in women with polycystic ovary syndrome, but can be increased by exenatide or metformin treatment.
    Zheng S; Liu E; Zhang Y; Long T; Liu X; Gong Y; Mai T; Shen H; Chen H; Lin R; Zheng Y; Xie Y; Wang F
    Endocr J; 2019 Jun; 66(6):555-562. PubMed ID: 30918134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Zinc-α2-glycoprotein levels and Insulin Resistance in Polycystic Ovary Syndrome.
    Lai Y; Chen J; Li L; Yin J; He J; Yang M; Jia Y; Liu D; Liu H; Liao Y; Yang G
    Sci Rep; 2016 May; 6():25934. PubMed ID: 27180914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between circulating zinc-α2-glycoprotein levels and the different phenotypes of polycystic ovary syndrome.
    Tang C; Li X; Tang S; Wang Y; Tan X
    Endocr J; 2020 Mar; 67(3):249-255. PubMed ID: 31748429
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Elevated circulating levels of irisin and the effect of metformin treatment in women with polycystic ovary syndrome.
    Li M; Yang M; Zhou X; Fang X; Hu W; Zhu W; Wang C; Liu D; Li S; Liu H; Yang G; Li L
    J Clin Endocrinol Metab; 2015 Apr; 100(4):1485-93. PubMed ID: 25675380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin decreases the adipokine vaspin in overweight women with polycystic ovary syndrome concomitant with improvement in insulin sensitivity and a decrease in insulin resistance.
    Tan BK; Heutling D; Chen J; Farhatullah S; Adya R; Keay SD; Kennedy CR; Lehnert H; Randeva HS
    Diabetes; 2008 Jun; 57(6):1501-7. PubMed ID: 18375437
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term combined treatment with exenatide and metformin for overweight/obese women with polycystic ovary syndrome.
    Ma RL; Deng Y; Wang YF; Zhu SY; Ding XS; Sun AJ
    Chin Med J (Engl); 2021 Nov; 134(23):2882-2889. PubMed ID: 34732660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of metformin and exenatide on pregnancy rate and pregnancy outcomes in overweight or obese infertility PCOS women: long-term follow-up of an RCT.
    Li R; Mai T; Zheng S; Zhang Y
    Arch Gynecol Obstet; 2022 Nov; 306(5):1711-1721. PubMed ID: 35829765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exenatide, Metformin, or Both for Prediabetes in PCOS: A Randomized, Open-label, Parallel-group Controlled Study.
    Tao T; Zhang Y; Zhu YC; Fu JR; Wang YY; Cai J; Ma JY; Xu Y; Gao YN; Sun Y; Fan W; Liu W
    J Clin Endocrinol Metab; 2021 Mar; 106(3):e1420-e1432. PubMed ID: 32995892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of exenatide on weight loss, metabolic parameters and pregnancy in overweight/obese polycystic ovary syndrome.
    Liu X; Zhang Y; Zheng SY; Lin R; Xie YJ; Chen H; Zheng YX; Liu E; Chen L; Yan JH; Xu W; Mai TT; Gong Y
    Clin Endocrinol (Oxf); 2017 Dec; 87(6):767-774. PubMed ID: 28834553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum vascular endothelial growth factor B is elevated in women with polycystic ovary syndrome and can be decreased with metformin treatment.
    Cheng F; Zhao L; Wu Y; Huang T; Yang G; Zhang Z; Wu Y; Jia F; Wu J; Chen C; Liu D
    Clin Endocrinol (Oxf); 2016 Mar; 84(3):386-93. PubMed ID: 26387747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of long-term treatment with metformin added to hypocaloric diet on body composition, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome.
    Pasquali R; Gambineri A; Biscotti D; Vicennati V; Gagliardi L; Colitta D; Fiorini S; Cognigni GE; Filicori M; Morselli-Labate AM
    J Clin Endocrinol Metab; 2000 Aug; 85(8):2767-74. PubMed ID: 10946879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proinsulin, adiponectin and hsCRP in reproductive age women with polycystic ovary syndrome (PCOS)--the effect of metformin treatment.
    Kruszyńska A; Słowińska-Srzednicka J; Jeske W; Zgliczyński W
    Endokrynol Pol; 2014; 65(1):2-10. PubMed ID: 24549596
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy.
    Diamanti-Kandarakis E; Spina G; Kouli C; Migdalis I
    J Clin Endocrinol Metab; 2001 Oct; 86(10):4666-73. PubMed ID: 11600523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of metformin compared with hypocaloric diet on serum C-reactive protein level and insulin resistance in obese and overweight women with polycystic ovary syndrome.
    Esfahanian F; Zamani MM; Heshmat R; Moini nia F
    J Obstet Gynaecol Res; 2013 Apr; 39(4):806-13. PubMed ID: 23279603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome.
    Koiou E; Tziomalos K; Katsikis I; Delkos D; Tsourdi EA; Panidis D
    Hormones (Athens); 2013; 12(4):559-66. PubMed ID: 24457404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome.
    Elkind-Hirsch K; Marrioneaux O; Bhushan M; Vernor D; Bhushan R
    J Clin Endocrinol Metab; 2008 Jul; 93(7):2670-8. PubMed ID: 18460557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome.
    Koiou E; Tziomalos K; Dinas K; Katsikis I; Kalaitzakis E; Delkos D; Kandaraki EA; Panidis D
    Endocr J; 2011; 58(4):237-46. PubMed ID: 21325745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical, metabolic and endocrine parameters in response to metformin in obese women with polycystic ovary syndrome: a randomized, double-blind and placebo-controlled trial.
    Chou KH; von Eye Corleta H; Capp E; Spritzer PM
    Horm Metab Res; 2003 Feb; 35(2):86-91. PubMed ID: 12734787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Retinol-binding protein 4 and insulin resistance in polycystic ovary syndrome.
    Hutchison SK; Harrison C; Stepto N; Meyer C; Teede HJ
    Diabetes Care; 2008 Jul; 31(7):1427-32. PubMed ID: 18390799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum anti-Müllerian hormone levels remain high until late reproductive age and decrease during metformin therapy in women with polycystic ovary syndrome.
    Piltonen T; Morin-Papunen L; Koivunen R; Perheentupa A; Ruokonen A; Tapanainen JS
    Hum Reprod; 2005 Jul; 20(7):1820-6. PubMed ID: 15802325
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.